EUVIMEDOpdag EUVIMED
Crossref

Design, synthesis, and anticancer evaluation of N 6 ‐hydrazone purine derivatives with potential antiplatelet aggregation activity

Chaochun Wei, Liying Zhou, Yifan Yang, Lexuan Niu, Hong Yan iD

Chemical Biology & Drug Design · 2023-03 · 101 (3) · 568-580

DOI: 10.1111/cbdd.14145 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2022-09-21. Written by Chaochun Wei and 4 co-authors. Institution: Faculty of Environment and Life, Beijing University of Technology, Beijing, China. Major MEDLINE topics: Vascular Endothelial Growth Factor Receptor-2, Antineoplastic Agents. Cited 11 times so far (Crossref); 58 references. Funded by: Natural Science Foundation of Beijing Municipality.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

In our research on novel anticancer agents, a series of N 6 ‐hydrazone purine derivatives were designed and synthesized by analysis of a pharmacophore model for ATP‐competitive inhibitors. The activities screening results showed that N 6 ‐hydrazone purine derivatives 21 and 26 not only showed potential antiproliferative activity against the A549 and MCF‐7 cell lines comparable to Vandetanib as a positive control but also had moderate antiplatelet aggregation activity. In order to investigate the possible targets, a molecular docking study was carried out on the fourteen kinases associated with anticancer and antiplatelet aggregation activities. The results indicated that compounds 21 and 26 had the potential activity to target VEGFR‐2, PI3Kα, EGFR, and HER2 kinases. The inhibition of the kinases assay showed that compound 26 could target VEGFR‐2, PI3Kα, and EGFR (IC 50 = 0.822, 3.040 and 6.625 μM). All results indicated that compound 26 will be an encouraging framework as potential new multi‐target anticancer agent with potential antiplatelet aggregation activity.

Subjects

MeSH terms (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsHumansStructure-Activity RelationshipMolecular Docking SimulationCell ProliferationHydrazonesDrug Screening Assays, AntitumorErbB ReceptorsPurinesDrug DesignProtein Kinase InhibitorsMolecular StructureIndazolesNitrofurans

Author keywords

N6-hydrazone derivatives of purineanticancerantiplatelet aggregationmolecular dockingsynthesis

Substances

Vascular Endothelial Growth Factor Receptor-2HydrazonesAntineoplastic AgentsErbB ReceptorsPurinesProtein Kinase Inhibitors3-(5-nitrofuryl)-7-(5-nitrofurfurylidene)-3,3a,4,5,6,7-hexahydro-2H-indazoleIndazolesNitrofurans

Authors and institutions

  • Faculty of Environment and Life, Beijing University of Technology, Beijing, China.
  • Beijing Tide Pharmaceutical Co., Ltd, Beijing, China.

ORCID profiles: Hong Yan

Funding

  • Natural Science Foundation of Beijing Municipality

Cite

APA

Wei, C., Zhou, L., Yang, Y., Niu, L., & Yan, H. (2023). Design, synthesis, and anticancer evaluation of N 6 ‐hydrazone purine derivatives with potential antiplatelet aggregation activity. Chemical Biology & Drug Design, 101(3), 568-580. https://doi.org/10.1111/cbdd.14145

Vancouver

Wei C, Zhou L, Yang Y, Niu L, Yan H. Design, synthesis, and anticancer evaluation of N 6 ‐hydrazone purine derivatives with potential antiplatelet aggregation activity. Chemical Biology & Drug Design. 2023;101(3):568-580. doi:10.1111/cbdd.14145

BibTeX
@article{Wei2023,
  author = {Wei, Chaochun and Zhou, Liying and Yang, Yifan and Niu, Lexuan and Yan, Hong},
  title = {Design, synthesis, and anticancer evaluation of N 6 ‐hydrazone purine derivatives with potential antiplatelet aggregation activity},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  volume = {101},
  number = {3},
  pages = {568--580},
  doi = {10.1111/cbdd.14145}
}
Start for free →